- Open
- 1704.00
- High
- 1753.00
- Low
- 1704.00
- Close
- 1729.00
- Change
- +4.00 (0.23%)
- Volume
- 72,123
| 21 Oct 2026 | 14:57:56 | Holding(s) in Company |
| 20 Oct 2026 | 14:46:47 | Holding(s) in Company |
| 24 Sept 2026 | 07:00:08 | Hikma appoints Rebecca Hall as CFO |
| 22 Sept 2026 | 12:00:01 | Hikma R&D Investor Spotlight Series |
| 18 Mar 2026 | 2025 Annual Report and Accounts | |
| 19 Mar 2025 | 2024 Annual Report and Accounts | |
| 22 Mar 2024 | 2023 Annual Report and Accounts |
Hikma Pharmaceuticals plc is a global pharmaceutical company that develops, manufactures, and markets a wide range of generic, specialty, and branded medications. Its operations are divided into three main segments: Injectables, which supplies hospitals with generic and specialty injectable products; Branded, which offers branded generics and in-licensed patented products primarily in the MENA region; and Hikma Rx, which provides oral and respiratory generic products to the North American retail market. Hikma operates manufacturing facilities and R&D hubs across North America, Europe, and the MENA region, serving healthcare providers and patients in over 50 countries.
| 21 Oct 2026 | 14:57:56 | Holding(s) in Company |
| 20 Oct 2026 | 14:46:47 | Holding(s) in Company |
| 24 Sept 2026 | 07:00:08 | Hikma appoints Rebecca Hall as CFO |
| 22 Sept 2026 | 12:00:01 | Hikma R&D Investor Spotlight Series |
| 18 Mar 2026 | 2025 Annual Report and Accounts | |
| 19 Mar 2025 | 2024 Annual Report and Accounts | |
| 22 Mar 2024 | 2023 Annual Report and Accounts |
Hikma Pharmaceuticals plc is a global pharmaceutical company that develops, manufactures, and markets a wide range of generic, specialty, and branded medications. Its operations are divided into three main segments: Injectables, which supplies hospitals with generic and specialty injectable products; Branded, which offers branded generics and in-licensed patented products primarily in the MENA region; and Hikma Rx, which provides oral and respiratory generic products to the North American retail market. Hikma operates manufacturing facilities and R&D hubs across North America, Europe, and the MENA region, serving healthcare providers and patients in over 50 countries.
| 22 Sept 2026 |
| 09:32:40 |
| Director/PDMR Shareholding |
| 25 Aug 2026 |
| Jefferies lifts Hikma target as CMO deal underpins growth story |
| 21 Aug 2026 | ii view: Hikma keeps a healthy pulse with solid first half |
| 12 Aug 2026 | Citi sees Hikma discount as unwarranted after upgrade to forecasts |
| 10 Aug 2026 | Hikma boost as broker raises price target |
| 6 Aug 2026 | FTSE 250 round-up: records, Harbour Energy, Hikma Pharma, OSB |
| 6 Aug 2026 | Hikma jumps 10% as brokers point to profit beat and undemanding rating |
| 22 Sept 2026 |
| 09:32:40 |
| Director/PDMR Shareholding |
| 25 Aug 2026 |
| Jefferies lifts Hikma target as CMO deal underpins growth story |
| 21 Aug 2026 | ii view: Hikma keeps a healthy pulse with solid first half |
| 12 Aug 2026 | Citi sees Hikma discount as unwarranted after upgrade to forecasts |
| 10 Aug 2026 | Hikma boost as broker raises price target |
| 6 Aug 2026 | FTSE 250 round-up: records, Harbour Energy, Hikma Pharma, OSB |
| 6 Aug 2026 | Hikma jumps 10% as brokers point to profit beat and undemanding rating |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £4.68bn | +0.0% | |
HIKHikma Pharmaceuticals plc | £3.61bn | -0.1% |
| £362m | -0.5% | |
| £287m | -0.1% | |
| £276m | +0.0% | |
| £237m | -0.5% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £4.68bn | +0.0% | |
HIKHikma Pharmaceuticals plc | £3.61bn | -0.1% |
| £362m | -0.5% | |
| £287m | -0.1% | |
| £276m | +0.0% | |
| £237m | -0.5% |